Modulation of adhesion molecule expression on endothelial cells after induction by lipopolysaccharide-stimulated whole blood

Scandinavian Journal of Immunology

Volumn 59, Issue 5, 2004, Pages 440-448

  Nooteboom, A ^a   Van Der Linden, C J ^b   Hendriks, T ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Atrium Hospital   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; DITHIOCARBAMIC ACID DERIVATIVE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 1 ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ARTICLE; BLOOD; CELL ACTIVATION; CELL CULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; PLASMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; REACTION TIME; STATISTICAL SIGNIFICANCE;

CELL ADHESION MOLECULES; CELLS, CULTURED; E-SELECTIN; ENDOTHELIAL CELLS; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; INTERLEUKIN-1; LIPOPOLYSACCHARIDES; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 2642555569     PISSN: 03009475     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0300-9475.2004.01413.x     Document Type: Article

References (39)

1. Bellingan G. Inflammatory cell activation in sepsis. Br Med Bull 1999;55:12-29.
2. McGill SN, Ahmed NA, Christou NV. Endothelial cells: role in infection and inflammation. World J Surg 1998;22:171-8.
3. Volk T, Kox WJ. Endothelium function in sepsis. Inflamm Res 2000;49:185-98.
4. Carlos TM, Harlan JM. Leukocyte-endothelial adhesion molecules. Blood 1994;84:2068-101.
5. Cines DB, Pollak ES, Buck CA et al. Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood 1998;91:3527-61.
6. Springer TA. Traffic signals on endothelium for lymphocyte recirculation and leukocyte emigration. Annu Rev Physiol 1995;57:827-72.
7. Collins T, Read MA, Neish AS, Whitley MZ, Thanos D, Maniatis T. Transcriptional regulation of endothelial cell adhesion molecules. NF-kappa B and cytokine-inducible enhancers. FASEB J 1995;9:899-909.
8. Melrose J, Tsurushita N, Liu G, Berg EL. IFN-gamma inhibits activation-induced expression of E- and P-selectin on endothelial cells. J Immunol 1998;161:2457-64.
9. Sttindhall J, Lundblad A, Pahlsson P. Interferon-gamma enhancement of E-selectin expression on endothelial cells is inhibited by monensin. Scand J Immunol 1997;46:338-43.
10. Marshall JC. Clinical trials of mediator-directed therapy in sepsis: what have we learned? Intensive Care Med 2000:26 (Suppl. 1):S75-S83.
11. Sharma VK, Dellinger RP. Recent developments in the treatment of sepsis. Expert Opin Investig Drugs 2003;12:139-52.
12. Reinhart K, Karzai W. Anti-tumor necrosis factor therapy in sepsis: update on clinical trials and lessons learned. Crit Care Med 2001;29:S121-S125.
13. Desch CE, Kovach NL, Present W, Broyles C, Harlan JM. Production of human tumor necrosis factor from whole blood ex vivo. Lymphokine Res 1989;8:141-6.
14. Roumen RM, Hendriks T, Van der V et al. Cytokine patterns in patients after major vascular surgery, hemorrhagic shock, and severe blunt trauma. Relation with subsequent adult respiratory distress syndrome and multiple organ failure. Ann Surg 1993;218:769-76.
15. Jaffe EA, Nachman RL, Becker CG, Minick CR. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J Clin Invest 1973;52:2745-56.
16. Leeuwenberg JF, Smeers EF, Neefjes JJ et al. E-selectin and intercellular adhesion molecule-1 are released by activated human endothelial cells in vitro. Immunology 1992;77:543-9.
17. Dinarello CA. Proinflammatory cytokines. Chest 2000;118:503-8.
18. Opal SM, Scannon PJ, Vincent JL et al. Relationship between plasma levels of lipopolysaccharide (LPS) and LPS-binding protein in patients with severe sepsis and septic shock. J Infect Dis 1999;180:1584-9.
19. Pugin J, Ulevitch RJ, Tobias PS. Tumor necrosis factor-alpha and interleukin-1 beta mediate human endothelial cell activation in blood at low endotoxin concentrations. J Inflamm 1995;45:49-55.
20. Nooteboom A, Hendriks T, van der Linden CJ. Tumor Necrosis Factor-aplha and Interleukin-1 beta mediate endothelial permeabilty induced by lipopolysaccharide stimulated whole blood. Crit Care Med 2002;30:2063-8.
21. Pugin J, Ulevitch RJ, Tobias PS. Activation of endothelial cells by endotoxin: direct versus indirect pathways and the role of CD14. Prog Clin Biol Res 1995;392:369-73.
22. Leeuwenberg JF, van Tits LJ, Jeunhomme TM, Buurman WA. Evidence for exclusive role in signalling of tumour necrosis factor p55 receptor and a potentiating function of p75 receptor on human endothelial cells. Cytokine 1995;7:457-62.
23. Akeson AL, Mosher LB, Woods CW, Schroeder KK, Bowlin TL. Human aortic endothelial cells express the type I but not the type II receptor for interleukin-1 (IL-1). J Cell Physiol 1992;153:583-8.
24. Louis E, Franchimont D, Piron A et al. Tumour necrosis factor (TNF) gene polymorphism influences TNF-alpha production in lipopolysaccharide (LPS)-stimulated whole blood cell culture in healthy humans. Clin Exp Immunol 1998;113:401-6.
25. Eggesbo JB, Hjermann I, Hostmark AT, Kierulf P. LPS induced release of IL-1 beta, IL-6, IL-8 and TNF-alpha in EDTA or heparin anticoagulated whole blood from persons with high or low levels of serum HDL. Cytokine 1996;8:152-60.
26. Foca A, Berlinghieri MC, Barreca GS et al. Kinetics of IL-8, MIP-1 alpha, TNF alpha, IL-1 beta, IL-1ra and IL-10 in human whole blood samples triggered by smooth and rough LPS. New Microbiol 1998;21:123-30.
27. Hordijk PL, Anthony E, Mul FP, Rientsma R, Oomen LC, Roos D. Vascular-endothelial-cadherin modulates endothelial monolayer permeability. J Cell Sci 1999;112:1915-23.
28. Bannerman DD, Sathyamoorthy M, Goldblum SE. Bacterial lipopolysaccharide distupts endothelial monolayer integrity and survival signaling events through caspase cleavage of adherens junction proteins. J Biol Chem 1998;273:35371-80.
29. Matcus BC, Wyble CW, Hynes KL, Gewertz BL. Cytokine-induced increases in endothelial permeability occur after adhesion molecule expression. Surgery 1996;120:411-6.
30. Pober JS. Activation and injury of endothelial cells by cytokines. Pathol Biol Paris 1998;46:159-63.
31. Pierce JW, Schoenleber R, Jesmok G et al. Novel inhibitors of cytokine-induced IkappaBalpha phosphorylation and endothelial cell adhesion molecule expression show anti-inflammatory effects in vivo. J Biol Chem 1997;272:21096-103.
32. Chen CC, Rosenbloom CL, Anderson DC, Manning AM. Selective inhibition of E-selectin, vascular cell adhesion molecule-1, and intercellular adhesion molecule-1 expression by inhibitors of I kappa B-alpha phosphorylation. J Immunol 1995;155:3538-45.
33. Tummala PE, Chen XL, Medford RM. NF-kappa B independent suppression of endothelial vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 gene expression by inhibition of flavin binding proteins and superoxide production. J Mol Cell Cardiol 2000;32:1499-508.
34. Eissner G, Kolch W, Mischak H, Bornkamm GW, Holler E. Differential role of protein kinase C in cytokine induced lymphocyte-endothelium interaction in vitro. Scand J Immunol 1994;40:395-402.
35. May MJ, Wheeler-Jones CP, Pearson JD. Effects of protein tyrosine kinase inhibitors on cytokine-induced adhesion molecule expression by human umbilical vein endothelial cells. Br J Pharmacol 1996;118:1761-71.
36. Boyle EM, Kovacich JC, Canty TG Jr et al. Inhibition of nuclear factor-kappa B nuclear localization reduces human E-selectin expression and the systemic inflammatory response. Circulation 1998;98:II282-II288.
37. Rahman A, Kefer J, Bando M, Niles WD, Malik AB. E-selectin expression in human endothelial cells by TNF-alpha-induced oxidant generation and NF-kappaB activation. Am J Physiol 1998;275:L533-L544.
38. Liu SF, Ye X, Malik AB. Pyrrolidine dithiocarbamate prevents I-kappaB degradation and reduces microvascular injury induced by lipopolysaccharide in multiple organs. Mol Pharmacol 1999;55:658-67.
39. Remick DG, Call DR, Ebong SJ et al. Combination immunotherapy with soluble tumor necrosis factor receptors plus interleukin 1 receptor antagonist decreases sepsis mortality. Crit Care Med 2001;29:473-81.